This company listing is no longer active
4UU Stock Overview
Diurnal Group plc operates as a specialty pharma company worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Diurnal Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.28 |
| 52 Week High | €0.79 |
| 52 Week Low | €0.08 |
| Beta | 0.34 |
| 1 Month Change | 2.92% |
| 3 Month Change | 250.31% |
| 1 Year Change | -59.13% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -16.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4UU | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.4% | -2.1% | -2.1% |
| 1Y | -59.1% | -15.6% | 2.1% |
Return vs Industry: 4UU underperformed the German Biotechs industry which returned -10.1% over the past year.
Return vs Market: 4UU underperformed the German Market which returned -26.6% over the past year.
Price Volatility
| 4UU volatility | |
|---|---|
| 4UU Average Weekly Movement | 51.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 4UU's share price has been volatile over the past 3 months.
Volatility Over Time: 4UU's weekly volatility has increased from 28% to 52% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 33 | Richard Bungay | www.diurnal.co.uk |
Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency.
Diurnal Group plc Fundamentals Summary
| 4UU fundamental statistics | |
|---|---|
| Market cap | €47.74m |
| Earnings (TTM) | -€18.98m |
| Revenue (TTM) | €5.36m |
9.2x
P/S Ratio-2.6x
P/E RatioIs 4UU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4UU income statement (TTM) | |
|---|---|
| Revenue | UK£4.68m |
| Cost of Revenue | UK£1.02m |
| Gross Profit | UK£3.66m |
| Other Expenses | UK£20.23m |
| Earnings | -UK£16.57m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.095 |
| Gross Margin | 78.16% |
| Net Profit Margin | -353.76% |
| Debt/Equity Ratio | 0.0% |
How did 4UU perform over the long term?
See historical performance and comparison